Compare BIO-TECHNE Corp (TECH) vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF (VTIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF — how do they compare? BIO-TECHNE Corp trades at $71.6 (market cap $11.16B), while Vanguard Sht-Term Inflation-Protected Sec Idx ETF trades at $49.65. The key difference: BIO-TECHNE Corp pays a 0.45% dividend while Vanguard Sht-Term Inflation-Protected Sec Idx ETF pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, Vanguard Sht-Term Inflation-Protected Sec Idx ETF nearer its low. Which is the better fit depends on your goals.
| TECH | VTIP | |
|---|---|---|
Market Cap | $11.16B | — |
Sector | Health | — |
52-Week High | $72.12 | $50.75 |
52-Week Low | $43.31 | $49.39 |
Enterprise Value | $11.24B | — |
Dividend Yield | 0.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $71.64, down 0.67% today, near its 52-week high following Merck KGaA's $73 per share acquisition offer. The stock shows bullish technical signals with strong moving averages, though RSI indicates overbought conditions. Recent earnings have been mixed, with Q4 2025 beating expectations but Q1 2026 missing. The company maintains solid gross margins of 64.96% but faces declining net income margins, down to 6.01% in 2025 from 25.09% in 2023.
The outlook is heavily influenced by the pending acquisition, offering a clear exit near current levels. Risks include shareholder litigation over deal fairness and fundamental profitability pressures. With a high P/E of 103.03, the stock's upside appears capped without the deal, while the $73 bid provides a near-term floor. Investors should weigh acquisition completion probability against operational challenges.
VTIP trades at $49.665, down 0.07% on the day, with a mixed technical outlook showing a bullish overall signal but bearish moving averages. The ETF focuses on short-term inflation-protected securities, offering a hedge against rising costs. Recent institutional buying includes a 239.8% position increase by Cwm LLC as of April 2026, signaling confidence. A dividend of $0.68 is scheduled for July 2026, providing income appeal.
Outlook remains cautious as the Fed signals no rate cuts in 2026, potentially limiting bond upside. VTIP's inflation hedge is relevant with CPI at 3.8% in April 2026, but short-term rate sensitivity poses risks. The ETF suits defensive portfolios seeking inflation protection, though volatility may persist amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Vanguard Sht-Term Inflation-Protected Sec Idx ETF
The index is a market-capitalization-weighted index that includes all inflation-protected public obligations issued by the US Treasury with remaining maturities of less than 5 years. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the securities that make up the index, holding each security in approximately the same proportion as its weighting in the index.
Read more on VTIP →
